<DOC>
	<DOC>NCT00171522</DOC>
	<brief_summary>To determine whether female patients have a preference for tegaserod of PEG 3350 relative to dosage form, convenience, ease of administration and taste</brief_summary>
	<brief_title>Preference of Tegaserod vs. PEG 3350 in Patients With Constipation</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Tegaserod</mesh_term>
	<mesh_term>Polyethylene glycol 3350</mesh_term>
	<criteria>Females aged 18 to 64 years of age Patients with constipation as defined by the Rome II criteria Patients who have been previously been treated with tegaserod and/or PEG 3350 Evidence of cathartic colon or a history of laxative abuse or laxative dependence History of fecal impaction which necessitated surgical intervention Patients with clinically significant abnormal TSH levels at screening Women who are pregnant or breast feeding Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Constipation</keyword>
	<keyword>Tegaserod</keyword>
	<keyword>Polyethylene Glycol 3350</keyword>
	<keyword>PEG</keyword>
</DOC>